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Geﬁtinib (GEF), an inhibitor for EGFR tyrosine kinase, potently induces autophagy in non-small cell lung
cancer (NSCLC) cell lines such as PC-9 cells expressing constitutively activated EGFR kinase by EGFR gene
mutation as well as A549 and H226 cells with wild-type EGFR. Unexpectedly, GEF-induced autophagy
was also observed in non-NSCLC cells such as murine embryonic ﬁbroblasts (MEF) and leukemia cell
lines K562 and HL-60 without EGFR expression. Knockout of EGFR gene in A549 cells by CRISPR/Cas9
system still exhibited autophagy induction after treatment with GEF, indicating that the autophagy in-
duction by GEF is not mediated through inhibiting EGFR kinase activity. Combined treatment with GEF
and clarithromycin (CAM), a macrolide antibiotic having the effect of inhibiting autophagy ﬂux, enhances
the cytotoxic effect in NSCLC cell lines, although treatment with CAM alone exhibits no cytotoxicity. GEF
treatment induced up-regulation of endoplasmic reticulum (ER)-stress related genes such as CHOP/
GADD153 and GRP78. Knockdown of CHOP in PC-9 cells and Chop-knockout MEF both exhibited less
sensitivity to GEF than controls. Addition of CAM in culture medium resulted in further pronounced GEF-
induced ER stress loading, while CAM alone exhibited no effect. These data suggest that GEF-induced
autophagy functions as cytoprotective and indicates the potential therapeutic possibility of using CAM
for GEF therapy. Furthermore, it is suggested that the intracellular signaling for autophagy initiation in
response to GEF can be completely dissociated from EGFR, but unknown target molecule(s) of GEF for
autophagy induction might exist.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Lung cancer has become the most common cause of death from
cancer, accounting for approximately 23% of all cancer-related
deaths in the world. In particular, non-small cell lung cancer
(NSCLC) accounts for about nine out of ten cases of all lung cancers
[1]. Small molecules for tyrosine kinase inhibitor (TKI) of epidermal
growth factor receptor (EGFR) such as geﬁtinib (GEF) and erlotinib
have become an effective therapy of choice for NSCLC patients
having EGFR-mutation [2,3]. Despite the initial response to EGFR-ry, Tokyo Medical University,
Fax: þ81 3 3351 6466.
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nd should be regarded as co-
Inc. This is an open access article uTKIs, most patients develop resistance, often due to the emer-
gence of a secondary mutation such as T790M, and eventually
relapse. The median survival of relapsed patients is reported to be
ﬁve to eight months at present [4]. Thus, a novel therapeutic
strategy for both aiming the cure at initial treatment, when the
NSCLC still has sensitivity to TKIs, and overcoming the resistance to
a secondary mutation appears to be urgent for improving thera-
peutic outcomes of NSCLC.
Autophagy, a highly conserved and regulated cellular process
employed by living cells to degrade proteins and organelles, has
been reported to be induced after treatment with EGFR-TKIs in
NSCLC and breast cancer cell lines [5,6]. Recent papers have sug-
gested that the induction of autophagy is indispensable for the
cytotoxic effect of EGFR-TKI in primary and resistant cells with
mutant EGFR-in NSCLC cells [7,8], while others have reported that
autophagy functions as cytoprotective as a response to metabolicnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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is associated with sensitivity or resistance to EGFR-TKIs. The most
recent report demonstrated that the accumulating inactivated
EGFR at endosome is critical for autophagy initiation via formation
of a complex with the autophagy inhibitor Rubicon in tumor cells
[12]. Association of inactivated EGFR with Rubicon in turn disas-
sociates Beclin 1 from Rubicon for autophagy initiation, which is
suggested to control tumor cell metabolism and promote tumor cell
survival [12].
We and others have reported that macrolide antibiotics
including clarithromycin (CAM) and azithromycin, both of which
are clinically well used antibiotics, have the effect of blocking
autophagy ﬂux [13e15]. We have also reported that bortezomib, a
proteasome inhibitor used for the treatment of patients with
multiplemyeloma, induces autophagy inmyeloma cell lines in vitro
[16]. Simultaneous inhibition of intracellular proteolytic processes
such as an ubiquitin-proteasome system with bortezomib and an
autophagy-lysosome systemwith CAM resulted in enhancement of
the apoptosis induction in myeloma cells along with accumulation
of intracellular polyubiquitinated proteins and aggresome forma-
tion [15,17]. Under the concomitant inhibition of two major intra-
cellular protein degradation systems, ER-tress loading was
pronounced, probably as a result of suppression of ERAD (ER
associated degradation) of ubiquitinated unfolded proteins. This
leads to ER-stress mediated apoptosis induction in myeloma and
breast cancer cells via up-regulation of CHOP (GADD153), a pro-
apoptotic-transcription factor [16e20]. In this context, ER-stress
loading appears to play a considerable role in apoptosis induction
in some cancer cells [21e23].
It is of interest that TKIs for BCR-ABL including imatinib and
dasatinib have been reported to induce autophagy in chronic
myeloid leukemia (CML) cells along with ER-stress [24,25]. CAM-
enhanced dasatinib-induced cell death in CML cells in vitro by
inhibiting late stage autophagy has also been reported [26]. In
several patients with resistant CML, oral administration of CAM
(500 mg, b.i.d.) was suggested to potentiate TKI-treatment,
although the molecular mechanism remains to be clariﬁed [27].
Based on these lines of evidence, we hypothesized that CAM
could enhance the cytotoxic effect of GEF along with ER-stress
loading in NSCLC. In the present study, we examined the com-
bined effect of GEF plus CAM as well as the biological roles of GEF-
induced autophagy in NSCLC cells by using CAM as an autophagy
inhibitor.
2. Material and methods
2.1. Reagents
Geﬁtinib (GEF) purchased from Cayman Chemical (Ann Arbor,
MI) was dissolved in dimethyl sulfoxide to make stock solutions at
concentrations of 10 mM. Clarithromycin (CAM) purchased from
Tokyo Chemical Industry (Tokyo, Japan) was dissolved in ethanol to
prepare stock solutions of 5 mg/ml. Lysosomal inhibitors E-64d and
pepstatin A were obtained from Peptide Institute (Osaka, Japan).
Doxycycline hydrochloride was purchased from Wako Pure
Chemicals Industries (Tokyo).
2.2. Cell lines and culture conditions
For this study, NSCLC cell lines such as PC-9 were obtained from
the RIKEN Bio Resource Center (Tsukuba, Japan), and A549 and
H226 were from the American Type Culture Collection (ATCC)
(Manassas, VA). Leukemia cell lines HL-60 and K562, along with a
Chop/ murine embryonic ﬁbroblast (MEF) cell line (CHOP-KO-
DR) established from a 13.5-day-old Chop/mouse embryo by SV-40 immortalization and a Chopþ/þ MEF cell line (DR-wild-type)
established by SV-40 immortalization as a control cell line for
CHOP-KO-DR, were also obtained from the ATCC. These authorized
cell lines were expanded and frozen in aliquots within one month
after they were obtained from the cell banks. Each aliquot was
thawed and the cells were used for the experiments within two
months after thawing. The NSCLC and leukemia cell lines were
cultured in RPMI-1640 medium (Sigma) supplemented with 10%
fetal bovine serum (FBS) (Biowest, Nuaille, France), 2 mM L-gluta-
mine, penicillin (100 U/ml), and streptomycin (100 mg/ml) (Wako).
CHOP-KO-DR and DR-wild-type cells were maintained in Dulbec-
co's modiﬁed Eagle's medium (Sigma) supplemented with 10% FBS,
2 mM L-glutamine, penicillin (100 U/ml), and streptomycin (100 mg/
ml). The m5-7 cell line, an Atg5 Tet-off MEF system, was a kind gift
from Dr. Noboru Mizushima (Tokyo University, Graduate School
and Faculty of Medicine, Tokyo, Japan). The culture conditions for
knockout of the Atg5 gene for inhibiting autophagy were previously
described in detail [28]. All cell lines were cultured in a humidiﬁed
incubator containing 5% CO2 and 95% air at 37 C.
2.3. Assessment of viable number of cells
The number of viable cells was assessed using CellTiter Blue, a
cell viability assay kit (Promega, Madison, WI), according to the
manufacturer's instructions as previously described in detail [15].
2.4. Immunoblotting
Immunoblotting was performed as previously described [15]. In
brief, cells were lysed with RIPA lysis buffer (Nacalai Tesque, Kyoto,
Japan) supplemented with a protease and phosphatase inhibitor
cocktail (Nacalai Tesque). Cellular proteins were separated by SDS-
PAGE and transferred onto Immobilon-P membrane (Millipore,
Billerica, MA). The membranes were probed with primary anti-
bodies (Abs): anti-LC3B Ab (Novus Biologicals, Littleton, CO), anti-
p62 (D-3) monoclonal (m) Ab, anti-GAPDH (6C5) mAb, anti-EGFR
(1005) Ab (Santa Cruz Biotechnology, Santa Cruz, CA), and anti-
cleaved caspase-3 Ab, anti-PARP Ab (Cell Signaling Technologies,
Danvers, MA). Speciﬁc Abs against tyrosine phosphorylated pro-
teins, such as anti-phosphotyrosine (4G10) mAb, were purchased
fromMillipore, and anti-phospho-EGFR (Tyr1173) Ab was obtained
from Santa Cruz Biotechnology. Immunoreactive proteins were
detected with horseradish peroxidase-conjugated secondary Abs
(Cell Signaling Technologies) and an enhanced chemiluminescence
reagent (Millipore). Densitometry was performed using a Molecu-
lar Imager, ChemiDoc XRS System (Bio-Rad).
2.5. Gene expression analysis
A real-time polymerase chain reaction (PCR) for gene expression
analysis was performed as we previously described in detail [15].
2.6. Knockout of ERGR gene by CRISPR/Cas9 emediated genome
editing and gene silence of CHOP by siRNA
Target sequences for CRISPR interference [29] were designed at
CRISPR direct (http://crispr.dbcls.jp/), provided by the Database
Center for Life Science (Chiba, Japan). The target sequences for
human EGFR are GGAGCAGCGATGCGACCCTC (Exon 1) or
TGCAAATAAAACCGGACTGA (Exon 3). Two complementary oligo-
nucleotides with BpiI restriction sites for guide RNAs (gRNAs) were
synthesized at Euroﬁns Genomics (Tokyo, Japan), and cloned into
pX459 CRISPR/Cas9-Puro vector (Addgene, Cambridge, MA)
deposited by the Feng Zhang Lab.
Fig. 1. Cell-growth inhibition and changes of intracellular protein tyrosine phosphorylation pattern after treatment with GEF. (A) All cell lines were treated with GEF at various
concentrations for 48 h. The viable cell number was assessed by CellTiter Blue as described in Materials and methods. (B) Cells were treated with/without 5 mM of GEF for 12 h. Cells
were lysed, and cellular proteins were separated by 7.5% SDS-PAGE and immunoblotted with anti-phosphotyrosine mAb, anti-EGFR Ab, and anti-phospho-EGFR (Tyr1173) Ab.
Immunoblotting with anti-GAPDH mAb was performed as an internal control.
Fig. 2. Autophagy induction after treatment with GEF. (A) Cells were treated with GEF at 5 and 25 mM for 24 he72 h. Cellular proteins were separated by 15% SDS-PAGE for LC3B and
11.25% SDS-PAGE for p62. Immunoblottings were performed using anti-LC3B Ab and anti-p62 mAb. Immunoblottings with anti-GAPDH mAb were performed as an internal control.
Because of the high cytotoxicity of GEF in some cell lines, it was difﬁcult to load the same amount of protein after 72 h exposure to GEF. Anti-p62 (D-3) mAb used in these ex-
periments reacts with human p62 but not with murine origin. (B) A549 cells were cultured with/without GEF (25 mM) in the presence or absence of lysosomal inhibitors (LIs), E-64d
(10 mg/ml) and pepstatin A (10 mg/ml) for 24 h. Cellular proteins were separated by 15% SDS-PAGE and immunoblotted with anti-LC3B Ab. (C) Two clones of A549 with EGFR gene
knocked out by the CRISPR/Cas9 method were treated with GEF at 5 and 25 mM for 72 h. Immunoblottings were performed using anti-EGFR Ab and LC3B Ab.
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amine 2000 (Life Technologies, Carlsbad, CA) according to the
manufacturer's instructions. Beginning the day after transfection,
these cells were treated with 2 mg/ml of puromycin for two days.
Surviving cells were reseeded at 0.5 cells per well of a 96-well plate.
Expressions of EGFR in the expanded colonies were detected by
immunoblotting using anti-EGFR (1005) Ab to select the EGFR-
depleted colonies. The genome sequences of the edited locus in
selected colonies were conﬁrmed by sequence analyses performed
at Euroﬁns Genomics.
Gene silence of CHOP in PC-9 cells by siRNA was performed as
previously described in detail [20].
2.7. Statistical analysis
All data are expressed as mean ± SD. The statistical analysis was
performed using ManneWhitney's U test (two-tailed).
3. Results and discussion
3.1. Cell growth inhibition in NSCLC and other cell lines after
treatment with GEF
As seen in Fig. 1A, GEF inhibited cell growth in NSCLC cell lines
tested in a dose-dependent manner: PC-9 cells with EGFRmutation
exhibited themost potent cell-growth inhibition in response to GEF
as compared with A549 and H226 cells, which are the cell lines
expressed with wild-type EGFR [30]. IC50 (50% inhibitory concen-
tration) after 48 h-exposure to GEF was 10.4 mM in PC-9 but wasFig. 3. CAM enhances the cytotoxic effect of GEF. (A) Autophagy ﬂux analysis in A549 cells:
described in Fig. 2B. Cellular proteins were separated by 15% SDS-PAGE and immunoblott
internal control for protein loading. (B) Cells were cultured with GEF at various concentratio
assessed as described in Materials and methods. (*p < 0.05：CAM () vs. CAM (þ)) (C) For
used [28]. After pre-treatment with/without doxycycline (Dox: 10 ng/ml) for 4 days, m5-7 cel
of the viable cell number and immunoblotting with anti-LC3B Ab were performed as descr33.4 mM in A459 and 26.0 mM inH226 cells. This was well correlated
with the clinical response, demonstrating that sensitizing EGFR
mutations are the most predictive factor for clinical beneﬁt with
EGFR TKIs [2,3]. The higher sensitivity of PC-9 cells to GEF can be
explained by the fact that they at least in part depend on the cell
growth and/or survival signals produced by ligand-independent
activation of mutant EGFR kinase. This is supported by our data
in Fig. 1B showing that, in contrast to A549 and H226 cells,
constitutive activated EGFR was observed in PC-9 cells, and that the
tyrosine phosphorylation of EGFR disappeared in response to GEF.
However, GEF exhibits considerable cell-growth inhibition in
MEF and non-EGFR expressing cell lines such as K562 (a CML cell
line with activated BCR-ABL kinase) and HL-60 cells (an AML cell
line) (Fig. 1A). (IC50s for these cell lines were 13.1 mM in MEF,
16.4 mM in K562, and 16.2 mM in HL-60.)
3.2. GEF induces autophagy in an EGFR-independent manner
Treating the cells with GEF resulted in an increased expression
ratio of LC3B-II to LC3B-I, which is a hallmark of autophagosome
formation by the conversion of cytosolic LC3B-I into lipidated LC3B-
II associated with autophagosome membrane in NSCLC cell lines
(Fig. 2A) [31]. P62, a substrate of autophagy, decreased in response
to GEF treatment. In addition, in the presence of lysosomal in-
hibitors (LIs) for blocking autophagy ﬂux, accumulation of GEF-
induced LC3B-II isoform was further enhanced as compared to
treatment with either GEF or LIs (Fig. 2A, B). All of these data
indicate that GEF induces autophagy in NSCLC cell lines as previ-
ously reported by others [5,8,9]. Strikingly, autophagy induction inCells were treated with CAM at 50 mg/ml in the presence or absence of LIs for 48 h as
ed with anti-LC3B Ab. Immunoblotting with anti-GAPDH mAb was performed as an
ns for 48 h in the presence or absence of CAM (50 mg/ml). The viable cell number was
complete inhibition of GEF-induced autophagy, a Atg5 Tet-off MEF cell line, m5-7, was
ls were further cultured in the presence or absence of GEF (25 mM) for 48 h. Assessment
ibed above. (*p < 0.05： Dox () vs. Dox (þ)).
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such as MEF, K562, and HL-60 cells. Since K562 and HL-60 are
leukemia cell lines derived from a mesoderm, they do not express
EGFR (Fig. 1B). Therefore, autophagy initiation by GEF appeared not
to be mediated through the inhibition of EGFR kinase activity. To
conﬁrm this, we knocked out EGFR with a CRISPR/Cas9 system in
A549 cells and examined whether autophagy still could be induced
by GEF treatment. As seen in Fig. 2C, A549-EGFR-KO clones (#1 and
#2) exhibited autophagy induction in response to GEF as well as
parental and control clones. Thus, the underlying molecular
mechanism for autophagy initiation is dissociated from EGFR ki-
nase inactivation and even from EGFR expression.3.3. CAM enhances GEF-induced cytotoxicity in NSCLC
In contrast to GEF treatment, autophagy ﬂux analysis revealed
that CAM treatment did not increase the LC3B-II isoform any
further as compared to either treatment with LIs or CAM plus LIs in
A549 cells (Fig. 3A), indicating that CAM inhibits autophagy ﬂux in
A549 cells as previously reported in myeloma and breast cancer
cells [15,20]. Next, we added CAM into the culture medium for
blocking GEF-induced autophagy. As seen in Fig. 3B, combined
treatment with GEF and CAM at 50 mg/ml efﬁciently created pro-
nounced cytotoxicity in NSCLC cell lines, whereas treatment with
CAM alone yielded no cytotoxicity. Notably, CAM also enhanced the
cytotoxic effect of GEF in K562, HL-60, and MEF cells. To further
conﬁrm that the enhanced cytotoxicity is due to blocking of auto-
phagy, we used a Atg5 Tet-off MEF cell line m5-7 [28]. Pre-
treatment with doxycycline (Dox) resulted in complete inhibitionFig. 4. ER-stress loading after treatment with GEF and/or CAM in NSCLC cell lines. (A) Kinet
and 48 h of exposure to GEF (25 mM), CAM (50 mg/ml), and GEF (25 mM) plus CAM (5
were standardized to GAPDH as an internal control. The expression levels of GRP78 and CHO
Chopþ/þMEF cell line were cultured in the presence of GEF at various concentrations with/wit
as described in Materials and methods. (*p < 0.05：Chop/MEF vs. Chopþ/þMEF, #p < 0.05
siRNA for 48 h. The cells were treated with/without GEF (25 mM; G) and CAM (50 mg/ml; C) f
anti-CHOP mAb. Immunoblotting with anti-GAPDHmAbwas performed as an internal contro
with/without GEF at various concentrations in the presence or absence of CAM (50 mg/ml) f
siRNA vs. CHOP siRNA, #p < 0.05: GEF alone vs. GEF þ CAM).of GEF-induced autophagy by knockout of the Atg5 gene, which is
essential for autophagy induction. Under this condition, GEF-
induced cytotoxicity was signiﬁcantly pronounced as compared
with that in Atg5þ/þ MEF cells (Fig. 3C).3.4. ER-stress loading in NSCLC after combined treatment with GEF
and CAM
We next examined whether ER-stress loading is involved in the
enhanced cytotoxicity. Expression of ER-stress related genes such
as CHOP and GRP78was up-regulated in response to GEF treatment
within 24 h. Combined treatment with GEF and CAM resulted in
pronounced gene expression, whereas treatment with CAM alone
produced almost no effect as comparedwith untreated control cells
(Fig. 4A). CHOP is an ER-stress related transcription factor that up-
regulates pro-apoptotic molecules such as Bim and Bax [15,21,22],
so we compared the cytotoxicity between Chop/MEF and Chopþ/
þMEF cell lines. Chop/MEF cells were less sensitive to GEF than
the Chopþ/þMEF cell line (Fig. 4B). In addition, knockdown of CHOP
in PC-9 cells by siRNA (PC-9 CHOP-KD cells) resulted in attenuation
of GEF-induced cytotoxicity (Fig. 4C), indicating that ER-stress-
mediated CHOP induction is involved in the cytotoxic effect of
GEF. However, enhanced cytotoxicity by combining CAM plus GEF
was still detectable in both the Chop/ MEF cell line and in PC-9
CHOP-KD cells (Fig. 4B, C). These data suggest that GEF plus CAM
did increase ER-stress loading including CHOP, but other mole-
cule(s) appeared to be involved in the pronounced cytotoxicity by
GEF plus CAM.ics of CHOP and GRP78 expressions assessed by quantitative real-time PCR during 24 h
0 mg/ml) in NCSLC cell lines. The data of the real-time PCR products for each gene
P were compared with those in untreated control cells. (B) A Chop/MEF cell line and
hout CAM (50 mg/ml) for 48 h. The number of viable cells was assessed by Cell TiterBlue
: GEF alone vs. GEF þ CAM) (C) PC-9 cells were treated with CHOP siRNA and control
or 24 h. Cellular proteins were separated by 11.25% SDS-PAGE and immunoblotted with
l for protein loading. Alternatively, after siRNA treatment, the cells were further treated
or 48 h. The number of viable cells was assessed by Cell TiterBlue. (*p < 0.05：control
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lines regardless of EGFR expression (Fig. 2). Since all of these cell
lines inhibited cell growth in response to GEF to a greater or lesser
degree, autophagymight be induced as ametabolic stress response.
However, comparing these cell lines, autophagy induction was not
well-correlated to cell-growth inhibition but occurred to almost the
same extent at 25 mM of GEF (Fig. 2A). According to our previous
report, imatinib induces autophagy in various cell lines regardless
of BCR-ABL expression, and, surprisingly, imatinib exhibited the
cytoprotective effect in non-BCR-ABL expressing cells [32]. In the
presence of imatinib, the variable cell number was signiﬁcantly
increased in HL-60 and MEF cells under serum deprivation [32].
These data suggest the existence of target molecule(s) of TKIs for
cytoprotective autophagy initiation that might be completely
dissociated from the primary target.
We here also present that CAM enhances the cytotoxicity of GEF
along with blocking GEF-induced cytoprotective autophagy. Since
CAM is a clinically well used macrolide antibiotic, this drug appears
to be a strong candidate for TKI-therapy for improving therapeutic
outcomes in NSCLC patients. Although CAM enhances the cyto-
toxicity of GEF alongwith ER-stress loading (Figs. 3 and 4), we could
not clearly detect pronounced apoptosis induction as assessed by
Annexin V staining nor could we detect cleavages of caspase-3 and
PARP or morphological apoptotic features such as chromatin
condensation, nuclear fragmentation, and formation of an
apoptotic body (Supplementary data, Figs. S1 to S3.). In addition,
Chop/MEF and PC-9 CHOP-KD cells, both of which should be
resistant against ER-stress mediated apoptosis, still exhibited pro-
nounced cytotoxicity after combined treatment (Fig. 4B, C).
Therefore, non-apoptotic cell death including necroptosis might be
involved in this phenomenon [33,34]. Further studies for identi-
fying the target molecule(s) for autophagy induction as well as
identifying the true executor(s) for pronounced cell death are
worthy of being carried out as the next step.Conﬂict of interest
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